Comparative Pharmacology
Head-to-head clinical analysis: ACTOPLUS MET XR versus ROSIGLITAZONE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTOPLUS MET XR versus ROSIGLITAZONE MALEATE.
ACTOPLUS MET XR vs ROSIGLITAZONE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTOPLUS MET XR combines pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating PPAR-γ, and metformin, a biguanide that decreases hepatic glucose production and improves peripheral glucose uptake.
Rosiglitazone is a thiazolidinedione that acts as a selective agonist at peroxisome proliferator-activated receptor-gamma (PPARγ). Activation of PPARγ increases insulin sensitivity in adipose tissue, skeletal muscle, and liver, leading to reduced hepatic gluconeogenesis and increased glucose uptake.
Initial dose: 15 mg pioglitazone/500 mg metformin hydrochloride extended-release orally once daily with evening meal. Titrate based on glycemic response, maximum dose 45 mg pioglitazone/2000 mg metformin hydrochloride extended-release per day.
4 mg orally once daily; may increase to 8 mg once daily after 12 weeks if inadequate glycemic response.
None Documented
None Documented
Pioglitazone: terminal half-life 3-7 hours (parent), 16-24 hours (active metabolites); clinical effect sustained due to metabolites. Metformin: terminal half-life 6.2 hours (plasma), elimination prolonged in renal impairment (creatinine clearance <60 mL/min).
Terminal elimination half-life is 3-4 hours; clinically relevant as dosing is twice daily to maintain steady-state concentrations.
Pioglitazone: predominantly hepatic metabolism, 15-30% excreted in urine as metabolites, ~20% in feces. Metformin: 90% renal excretion unchanged via glomerular filtration and tubular secretion.
Primarily hepatic metabolism via CYP2C8, with less than 1% excreted unchanged in urine. Fecal excretion of metabolites accounts for approximately 64% and renal excretion for 23% of the dose.
Category C
Category A/B
Thiazolidinedione/Biguanide Combination
Thiazolidinedione